China Distributor Consolidation Heats Up: Sinopharm Looks To Raise $440 Million Ahead Of Shanghai Pharma IPO
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's largest drug distributor Sinopharm Group Co. Ltd. April 25 placed a secondary offering of roughly 138 million H shares in Hong Kong looking to raise HK$3.4 billion ($440 million) to fund more acquisitions. The move comes just ahead of the initial public offering in Hong Kong of Sinopharm's biggest competitor Shanghai Pharmaceutical Holdings Co. Ltd, and will add more heat to the consolidation war in China's distribution sector
You may also be interested in...
Sinopharm Positions Itself For MNCs That May Need To Change Sales Models In China
China’s largest pharmaceutical distributor has built up a web of subsidiaries to expand its manufacturing and distribution capabilities. The company said global pharma companies may need to change their sales models in China as a result of corruption probes and it wants to be first in line to help.
China’s Fosun Pharma Targets $650 Million IPO With Prudential Insurance As Cornerstone Investor
China’s largest non-state-owned pharma company Fosun Pharma commenced an initial global offering in Hong Kong, and nearly half of the money raised will be used for M&A. But the $650 million expected to be raised is much smaller than the rumored $800 million.
China’s Fosun Pharma Targets $650 Million IPO With Prudential Insurance As Cornerstone Investor
China’s largest non-state-owned pharma company Fosun Pharma commenced an initial global offering in Hong Kong, and nearly half of the money raised will be used for M&A. But the $650 million expected to be raised is much smaller than the rumored $800 million.